A Phase Ib Clinical Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Cisplatin and Pemetrexed in Treatment-naive Participants With Advanced Malignant Pleural Mesothelioma (KEYNOTE-A17).

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
Indications Malignant-mesothelioma
Focus Adverse reactions
Acronyms KEYNOTE-A17
Sponsors Merck Sharp & Dohme

Most Recent Events

29 Sep 2022 Status changed from active, no longer recruiting to completed.
12 Aug 2022 Planned End Date changed from 1 Dec 2022 to 21 Sep 2022.
09 Jun 2022 Planned End Date changed from 1 Jun 2023 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight